Abstract
Several recent studies have emphasized a crucial role for the nitrergic system in movement control and the pathophysiology of the basal ganglia (BG). These observations are supported by anatomical evidence demonstrating the presence of nitric oxide synthase (NOS) in all the basal ganglia nuclei. In fact, nitrergic terminals have been reported to make synaptic contacts with both substantia nigra dopamine-containing neurons and their terminal areas such as the striatum, the globus pallidus and the subthalamus. These brain areas contain a high expression of nitric oxide (NO)-producing neurons, with the striatum having the greatest number, together with important NO afferent input. In this paper, the distribution of NO in the BG nuclei will be described. Furthermore, evidence demonstrating the nitrergic control of BG activity will be reviewed. The new avenues that the increasing knowledge of NO in motor control has opened for exploring the pathophysiology and pharmacology of Parkinson's disease and other movement disorders will be discussed. For example, inhibition of striatal NO/guanosine monophosphate signal pathway by phosphodiesterases seems to be effective in levodopa-induced dyskinesia. However, the results of experimental studies have to be interpreted with caution given the complexities of nitrergic signalling and the limitations of animal models. Nevertheless, the NO system represents a promising pharmacological intervention for treating Parkinson's disease and related disorders.
Keywords: Nitric oxide, Basal Ganglia, Parkinson's Disease, Dyskinesia, Selective nitrergic drugs, GABA, Medical Medullary Lamina, SNOG, SIN-1, L-DOPA
CNS & Neurological Disorders - Drug Targets
Title: Nitric Oxide Modulation of the Basal Ganglia Circuitry: Therapeutic Implication for Parkinson's Disease and Other Motor Disorders
Volume: 10 Issue: 7
Author(s): Massimo Pierucci, Salvatore Galati, Mario Valentino, Vincenzo Di Matteo, Arcangelo Benigno, Alessandro Pitruzzella, Richard Muscat and Giuseppe Di Giovanni
Affiliation:
Keywords: Nitric oxide, Basal Ganglia, Parkinson's Disease, Dyskinesia, Selective nitrergic drugs, GABA, Medical Medullary Lamina, SNOG, SIN-1, L-DOPA
Abstract: Several recent studies have emphasized a crucial role for the nitrergic system in movement control and the pathophysiology of the basal ganglia (BG). These observations are supported by anatomical evidence demonstrating the presence of nitric oxide synthase (NOS) in all the basal ganglia nuclei. In fact, nitrergic terminals have been reported to make synaptic contacts with both substantia nigra dopamine-containing neurons and their terminal areas such as the striatum, the globus pallidus and the subthalamus. These brain areas contain a high expression of nitric oxide (NO)-producing neurons, with the striatum having the greatest number, together with important NO afferent input. In this paper, the distribution of NO in the BG nuclei will be described. Furthermore, evidence demonstrating the nitrergic control of BG activity will be reviewed. The new avenues that the increasing knowledge of NO in motor control has opened for exploring the pathophysiology and pharmacology of Parkinson's disease and other movement disorders will be discussed. For example, inhibition of striatal NO/guanosine monophosphate signal pathway by phosphodiesterases seems to be effective in levodopa-induced dyskinesia. However, the results of experimental studies have to be interpreted with caution given the complexities of nitrergic signalling and the limitations of animal models. Nevertheless, the NO system represents a promising pharmacological intervention for treating Parkinson's disease and related disorders.
Export Options
About this article
Cite this article as:
Pierucci Massimo, Galati Salvatore, Valentino Mario, Di Matteo Vincenzo, Benigno Arcangelo, Pitruzzella Alessandro, Muscat Richard and Di Giovanni Giuseppe, Nitric Oxide Modulation of the Basal Ganglia Circuitry: Therapeutic Implication for Parkinson's Disease and Other Motor Disorders, CNS & Neurological Disorders - Drug Targets 2011; 10 (7) . https://dx.doi.org/10.2174/187152711798072329
DOI https://dx.doi.org/10.2174/187152711798072329 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design Thymoquinone Lipid Nanoparticles Cut the Gordian Knots of Depression via Neuroprotective BDNF and Downregulation of Neuro-inflammatory NF-κB, IL-6, and TNF-α in LPS Treated Rats
Current Drug Metabolism Neuroprotective Role of Agmatine in Neurological Diseases
Current Neuropharmacology Beyond the Synapse and Hebb's Rule: Is the Rest of the Neuron More Important for Psychiatric Disorders?
Current Psychiatry Reviews Effects of Snake Venom Polypeptides on Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Gene Therapy for Brain Cancer: Combination Therapies Provide Enhanced Efficacy and Safety
Current Gene Therapy Kinematic and Pressure Features of Handwriting and Drawing: Preliminary Results Between Patients with Mild Cognitive Impairment, Alzheimer Disease and Healthy Controls
Current Alzheimer Research The Therapeutic Potential of Melatonin in Neurological Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Systems Biology Experimental Design - Considerations for Building Predictive Gene Regulatory Network Models for Prokaryotic Systems
Current Genomics Regulation of Postsynaptic Stability by the L-type Calcium Channel Ca<sub>V</sub>1.3 and its Interaction with PDZ Proteins
Current Molecular Pharmacology Innovations to Control the Environment for Persons with Movement Disorders: Support in Home Care
Recent Patents on Biomedical Engineering (Discontinued) Regulation of Insulin Release at Pre-exocytotic Stages of the Secretory Process
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Targeting Epidermal Growth Factor Receptor in Solid Tumors: Critical Evaluation of the Biological Importance of Therapeutic Monoclonal Antibodies
Current Medicinal Chemistry Commentary: Hot, Hotter, and Hottest Trends in α-Synuclein Research
Current Protein & Peptide Science New Patents on Topical Anesthetics
Recent Patents on Inflammation & Allergy Drug Discovery Effects and Perspectives of Chinese Patent Medicines for Tonifying <i>Qi</i> and Promoting Blood Circulation on Patients with Cerebral Infarction
Current Vascular Pharmacology The Role of Amitriptyline in the Management of Non-small Cell Lung Cancer
Current Cancer Therapy Reviews Contribution of Canalicular Glutathione Efflux to Bile Formation. From Cholestasis Associated Alterations to Pharmacological Intervention to Modify Bile Flow
Current Drug Targets - Immune, Endocrine & Metabolic Disorders An Effective Brain Imaging Biomarker for AD and aMCI: ALFF in Slow-5 Frequency Band
Current Alzheimer Research The Role of Binding Kinetics in GPCR Drug Discovery
Current Topics in Medicinal Chemistry